CE-MRI Captures Failing Lower-Limb Flow in Peripheral Artery Disease
Peripheral artery disease is often measured at the bedside with ankle-brachial index testing and walking performance, but those tools do not fully describe how blood moves through the calf arteries during first-pass perfusion. In this study, contrast-enhanced magnetic resonance imaging offered a more granular look at arterial signal dynamics in the lower extremities, where atherosclerotic narrowing and microvascular dysfunction can coexist and amplify exertional leg pain.
The cohort included 56 participants: 36 patients with peripheral artery disease and intermittent claudication, and 20 matched controls. Imaging focused on the mid-calf level and quantified first-pass perfusion in the anterior tibialis, posterior tibialis, and peroneal arteries. From those signal curves, investigators derived arterial signal intensity measures that captured signal enhancement, time to peak enhancement, the slope of enhancement, and area under the curve. In practical terms, those measures trace how quickly contrast arrives, how high the signal rises, and how long it persists inside the vascular bed.
A single observation drives the entire physiologic story: controls showed stronger arterial signal enhancement than patients with claudication.
Signal Enhancement Fell in Claudication, and the Pattern Was Measurable
Across the major lower-extremity arteries, higher signal enhancement, longer or altered time-to-peak behavior, and larger area under the curve were seen in matched controls than in patients with PAD. The direction of effect fits the vascular biology of the disease. When large-vessel stenosis, diffuse atherosclerosis, and impaired distal perfusion reduce arterial inflow, contrast arrival becomes blunted and the enhancement curve loses amplitude. The imaging readout therefore serves as a physiologic fingerprint of impaired circulation rather than a simple anatomic snapshot.
The study did not stop at a group comparison. It also examined composite or envelope measures that summarize arterial behavior across vessels and across legs. Those composite metrics again separated patients from controls and provided a way to capture the integrated effect of disease burden across the calf arterial network. For clinicians, that matters because PAD is rarely confined to one focal lesion; it is a systemic vascular disorder that can express itself unevenly from one artery, one calf, or one limb to the next.
Diabetes Amplified the Imaging Differences Without Moving the Usual Bedside Markers
Several CE-MRI variables differed significantly between patients with PAD who had concomitant diabetes and those who did not. Time to peak enhancement, signal enhancement, and area under the curve were among the measures that separated the two groups. Diabetes is a plausible amplifier of this signal because it accelerates endothelial dysfunction, promotes diffuse atherosclerosis, and worsens microvascular flow reserve. The result can be a more rigid and less responsive arterial tree, which would be expected to blunt enhancement dynamics on MRI.
What makes the finding clinically sharp is what did not move. Resting and exercise ankle-brachial index, treadmill peak walking time, claudication onset time, calf muscle area, and renal function did not distinguish those subgroups in the same way. In other words, the imaging readout was more sensitive than several conventional measures for capturing vascular differences tied to diabetes status. That suggests a role for CE-MRI when the clinical question is not simply whether PAD exists, but how severely blood flow dynamics are compromised in a patient already known to have the disease.
Side-to-Side Limb Asymmetry Exposed Uneven Perfusion Burden
When both legs were analyzed together, patients with PAD showed significant arterial hemodynamic asymmetry. The target leg had reduced signal enhancement, altered time-to-peak behavior, and lower area under the curve compared with the contralateral limb. This asymmetry is not a trivial statistical detail. PAD often presents with asymmetric anatomic disease, collateral formation, and variable distal runoff, and those features can produce measurable differences in perfusion between legs even when symptoms seem broadly similar.
Among patients with diabetes, the asymmetry became more pronounced. Maximum and median time to peak enhancement, maximum area under the curve, summed area under the curves, and envelope area under the curve were all lower in the target leg than in the opposite limb. The signal here is biologically coherent: diabetic vasculopathy can deepen the gap between a relatively preserved limb and one with more advanced occlusive disease. For an individual patient, that pattern may help explain why one calf burns first, why one side fatigues sooner, and why exercise tolerance can feel inconsistent from day to day.
Why These MRI Measures Could Matter at the Bedside
Current PAD assessment still leans heavily on symptoms, pulse examination, ABI, and exercise testing. Those tools are useful, but they do not directly visualize the dynamics of arterial inflow at the tissue level. CE-MRI-derived arterial signal-enhancement measures attempt to fill that gap by quantifying the actual passage of contrast through the lower-extremity arterial system. Because the variables capture enhancement magnitude and timing, they are sensitive to both macrovascular obstruction and downstream hemodynamic consequences.
Several of the proposed measures were associated with established clinical markers of PAD. That alignment gives the imaging approach face validity: it is not floating free from the disease state, but instead tracks with the physiology clinicians already recognize. At the same time, the stronger separation seen in diabetes and the clear limb asymmetry suggest the imaging metrics may detect disease features that ABI and treadmill testing leave blurred. In patients with intermittent claudication, especially those with diabetes, that could open a path toward more refined phenotyping of disease severity and vascular burden.
A Small Study With a Narrower Clinical Question Than Routine PAD Testing
This was a focused study, not a practice-changing outcomes trial. The sample was modest, and the work was designed to evaluate imaging-derived hemodynamics rather than hard clinical endpoints such as limb loss, revascularization, myocardial infarction, or mortality. The study therefore supports physiologic discrimination, not treatment selection or prognostic claims beyond the observed associations.
Even so, the message from the data is hard to ignore. Contrast-enhanced MRI distinguished PAD from matched controls, exposed stronger abnormalities in patients with diabetes, and revealed measurable asymmetry between legs. For a disease defined by impaired blood delivery, those are not abstract image findings; they are direct readouts of vascular failure in motion. The next step is not to ask whether the curves differ, but whether they can be linked to serial disease monitoring, procedural planning, or outcome prediction in larger cohorts with longer follow-up.